Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy.
Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, Christofyllakis K, Altmeyer S, Bick A, Stilgenbauer S, Bittenbring JT, Kaddu-Mulindwa D. Rixecker T, et al. Among authors: lesan v. Bone Marrow Transplant. 2021 Jan;56(1):195-201. doi: 10.1038/s41409-020-01003-0. Epub 2020 Jul 23. Bone Marrow Transplant. 2021. PMID: 32704092
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Kaddu-Mulindwa D, et al. Among authors: lesan v. Leuk Lymphoma. 2022 Feb;63(2):326-334. doi: 10.1080/10428194.2021.1975193. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668817
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V, Bittenbring JT, Thurner L, Pfreundschuh M, Christofyllakis K, Truemper L, Loeffler M, Schmitz N, Hoth M, Hallek M, Fischer K, Stilgenbauer S, Bewarder M, Rixecker TM. Kaddu-Mulindwa D, et al. Among authors: lesan v. Lancet Haematol. 2022 Feb;9(2):e133-e142. doi: 10.1016/S2352-3026(21)00369-0. Lancet Haematol. 2022. PMID: 35114151 Clinical Trial.
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients.
Kos I, Balensiefer B, Lesan V, Kaddu-Mulindwa D, Thurner L, Christofyllakis K, Bittenbring JT, Ahlgrimm M, Seiffert M, Wagenpfeil S, Bewarder Y, Neumann F, Rixecker T, Smola S, Link A, Krawczyk M, Lammert F, Lepper PM, Bals R, Stilgenbauer S, Bewarder M. Kos I, et al. Among authors: lesan v. Eur J Immunol. 2021 Jun;51(6):1449-1460. doi: 10.1002/eji.202049163. Epub 2021 Apr 19. Eur J Immunol. 2021. PMID: 33788264 Free PMC article. Clinical Trial.
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.
Yordanova K, Stilgenbauer S, Bohle RM, Lesan V, Thurner L, Kaddu-Mulindwa D, Bittenbring JT, Scharberger M, Aßmann G, Bewarder M. Yordanova K, et al. Among authors: lesan v. Br J Haematol. 2019 Sep;186(6):e203-e207. doi: 10.1111/bjh.16082. Epub 2019 Jul 1. Br J Haematol. 2019. PMID: 31257571 Free article. No abstract available.
IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.
Kaddu-Mulindwa D, Keuser L, Lesan V, Rissland J, Smola S, Werdecker V, Stilgenbauer S, Christofyllakis K, Thurner L, Bewarder M, Lohr B, Lutz J, Lohse S, Rieke A. Kaddu-Mulindwa D, et al. Among authors: lesan v. HIV Med. 2022 May;23(5):564-569. doi: 10.1111/hiv.13207. Epub 2021 Nov 22. HIV Med. 2022. PMID: 34811869 Free PMC article.
23 results